Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis.
OBJECTIVE
To describe 1-year clinical results of intravitreal ranibizumab treatment in patients with choroidal neovascularization secondary to exudative age-related macular degeneration (AMD) and to evaluate whether early treatment is a predictive value for prognosis of the disease.


METHODS
Clinical records were retrospectively reviewed of 104 eyes that underwent intravitreal ranibizumab therapy for exudative AMD. Patients were divided into two groups according to their symptom duration: group 1, <1 month; and group 2, 1-3 months. After three monthly injections, patients were examined monthly, and subsequent injections were performed as needed.


RESULTS
There were 43 female (48.9%) and 45 males (51.1%). The follow-up time was 13.7±1.9 (12-19) months. The mean logarithm of minimum angle of resolution best-corrected visual acuity (BCVA) improved significantly, from 0.45±0.639 at baseline to 0.08±0.267 at 12 months in group 1, and from 1.06±0.687 at baseline to 0.75±0.563 at 12 months in group 2. The increase in BCVA was statistically significant in group 1 (P=0.009). The mean central retinal thickness (CRT) decreased significantly, from 355.13±119.93 μm at baseline to 250.85±45.48 μm at 12 months in group 1, and from 371.88±91.047 μm at baseline to 268.61±53.51 μm at 12 months in group 2. The decrease in CRT was statistically significant in group 1 (P=0.001).


CONCLUSIONS
Intravitreal ranibizumab therapy was effective in significantly increasing mean BVCA and reducing CRT. Shorter duration of AMD, as measured by the subjective duration of visual symptoms, is associated with better visual outcome after treatment.
Department of Ophthalmology, Adana Teaching and Medical Research Center, Başkent University School of Medicine, Ankara, Turkey.
Handan
H
Canan
Department of Ophthalmology, Çukurova University School of Medicine, Ankara, Turkey.
Selçuk
S
Sızmaz
Department of Ophthalmology, Adana Teaching and Medical Research Center, Başkent University School of Medicine, Ankara, Turkey.
Rana
R
Altan-Yaycıoğlu
Department of Biostatistics, Adana Teaching and Medical Research Center, Başkent University School of Medicine, Ankara, Turkey.
Cağla
C
Sarıtürk
Department of Ophthalmology, Başkent University School of Medicine, Ankara, Turkey.
Gürsel
G
Yılmaz
D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections / Q000379:methods; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000069579:Ranibizumab; D012160:Retina / Q000187:drug effects / Q000473:pathology; D012189:Retrospective Studies; D013997:Time Factors; D014792:Visual Acuity / Q000187:drug effects
D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab
age-related macular degeneration (AMD); optical coherence tomography (OCT); ranibizumab; visual acuity